Copy of a post I just made on another site:
To all
Copy of a post I just made on another site:
To all posters in general who are greatly disappointed in the company and management in particular, some basic questions regarding who to blame for your disappointment:
1) Have you ever known of a company in biotech, where the odds of any drug reaching commerciality are extremely poor, having a rise in share price prior to generation of revenues or at a point of development where odds of commerciality are greatly increased due to clinical trials progress?
Sure, a couple of companies sign nice partnership deals early in development but they are few and far between and normally they give up the ship for possible future large returns to get said partnerships.
2) Then at what stage in the trials did you expect to see a nice return on your investment in IPIX?
I would say anything prior to end of phase 2 is out of the question.
3) Did mgt not let you know years ago that their plan was to partner out their indications only after all had passed Phase 2 trials so that they could maximize stockholder return as they thought the drugs in the pipeline each had massive potential and they didn't want to sell that for pennies on the dollar prior to proving their full value?
Now when will we have knowledge as to all Phase 2 results? Oh yeah, it is in 7 weeks or less.
4) Will all shareholders acknowledge that the stock has been under the shorts microscope since way prior to the Mako article and the Mako article was the attempt to drive the share price to a level that would bankrupt the company and has hampered their ability to raise monies at a rate they could have attained except for the gross attack, lies, and deception put out by the Seeking Alpha article and which also laid bare company coffers to fight said article in court?
5) Did not the inventor of Prurisol and Kevetrin pay out of his own pocket to Aruda shares because they made an administrative error at the beginning of the company that would have made clear Aruda had no right to claiming developmental rights? Did he not also cut his salary in half seeing that he no longer had massive lab duties and thus thought it unfair he keep receiving the larger salary than he though he was now due? Has the CEO, who has lent his own money to IPIX to keep it going, shown any signs of outrageous spending habits and an out-of-control lifestyle as intimated by some posts on this board?
6) Do not all stockholders know that IPIX, and thus mgt, is currently in a quiet period by law due to the ongoing negotiations with BP CDA partners and thus Leo has no option as to whether he can release any word whatsoever that would put such negotiations at risk?
I think the above questions make my point that it is not mgt who is at fault for how the company has progressed over the last few years and that those doing all the complaining either invested in a sector (biotech) that is far beyond their investing level as to being able to do proper DD and know about the myriad obstacles confronting the company to reach a stage where revenues start rolling in.
We are now 7 weeks at most from a date when we should start hearing some of the actual developments that have been going on backstage regarding IPIX and if they are going as one would hope we will start to soon see a rise in share price, perhaps a very nice rise in share price.
If you are still POd at this investment, just look in the mirror and acknowledge you are the cause for investing here and don't try to make IPIX mgt the scapegoat.
13
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Another Day, Another Leadership Shuffle at ATD Well, the wheel's turning again at American Tire Distributors (ATD). The crew in Huntersville, N.C., just put Michael Broderick in the driver's seat as Interim President, replacing Ira B. Silver. And they've parted ways with him—done and dusted. This isn't just some random pick; Broderick's been kickin' around ATD's Board...
Continue Reading
The Harmony of Fabric and Form Diving into how INSIS defines 'Natural Ease' is like watching an artist paint with subtlety. They’re moving beyond the mere appeal of their fabrics to craft a quieter conversation between the fabric, the body, and everyday life. They focus heavily on the material—17.5-micron superfine Aussie merino wool takes center stage, backed up by...
Continue Reading
Dr. Deborah Schult: A Pioneer in Correctional Healthcare If you've been in the business of behavioral healthcare, particularly in correctional environments, then you know the name Dr. Deborah Schult is one that resonates with seasoned respect. This year's People Helping People Award from the American Board of Correctional Psychology shines a well-deserved spotlight on her...
Continue Reading
Looking Ahead: JELD-WEN's Q3 Results Exploration Alright folks, buckle up. JELD-WEN Holding, Inc., the name any DIY'er worth their salt recognizes for doors and windows, has set the stage for unveiling its third quarter 2026 performance. They've earmarked November 3 post-market for us to comb through the numbers, and they're wasting no time by getting on a conference call...
Continue Reading
Is ODP Getting a Raw Deal? Grab a cup of joe, because this is one of those sticky situations where the stakes are high, and the details are grimmer than last week's sales report. On August 19, 2026, Monteverde & Associates PC filed a lawsuit targeting the acquisition of The ODP Corporation by Atlas Holdings LLC, claiming the buyout price wasn't just low—it was roaringly...
Continue Reading
A New Captain at Simpli.fi's Helm In the fast-paced world of digital advertising, Simpli.fi isn't just sitting on the sidelines. They've gone and snagged Sean McCaffrey as their new CEO. Now, for those who remember GSTV's rise to 30,000 locations under McCaffrey, this appointment carries some serious weight. McCaffrey's Track Record: Setting the Pace McCaffrey's no...
Continue Reading
DaVita Stands Firm on Kidney Care Innovation The healthcare landscape's shifting undercurrent, folks, and kidney care has landed smack in the spotlight with the U.S. Department of Health and Human Services (HHS) putting forth its Kidney Care National Plan. Now, this isn't some bureaucratic mumbo-jumbo—this plan's setting the tone for kidney disease treatment across...
Continue Reading
Picture a small business breaking into the spotlight, grabbing the industry’s attention two years in a row: That’s the story of Arbor Scientia Group (ASG), bagging its second consecutive BASA Award. Celebrated within the Education and Training category, this global medical education and communications agency—not just a regular name in the field—has made measurable...
Continue Reading
Anita Eno's Well-Deserved Recognition You've got to respect a story where someone claws their way up from humble beginnings to a position of serious influence. Anita Eno, Founder and CEO of Prayers Are Answered Inc., is one of those impressive figures, recently bagging the 2027 American Business Woman of the Year title. This accolade, dished out by the American Business...
Continue Reading
The dairy blends market, set to barrel towards USD 15.38 billion by 2035 according to Credence Research, isn't just a numbers game. It's a tug-of-war between different fats, regions, and regulations. For those betting on future market movements, this shouldn't be a passing glance. Rising from USD 9.97 billion in 2025, these figures suggest consistent waves rather than...
Continue Reading
Top 5 Most Recently Viewed Articles
SMArtX Advisory Solutions Unveils New Investment Strategies RSW Investments Joins the SMArtX Platform SMArtX Advisory Solutions, a prominent innovator in the managed accounts technology sector, has unveiled exciting new offerings to its Manager Marketplace. The platform now showcases a total of 1,566 strategies sourced from 322 respected asset management firms. The recent...
Continue Reading
Bahamas Government Enhances Notes Purchase Offer The Government of The Bahamas has made significant strides in engaging with its noteholders through an improved offer to purchase its outstanding notes. This move is geared towards providing timely cash options while managing its financial obligations effectively. Originally set at a maximum amount of U.S. $210,000,000, the...
Continue Reading
Evergy Inc: Current Stock Performance Overview Evergy Inc is currently experiencing an intriguing session in the stock market, trading at $72.88 following a substantial 1.86% increase. If we glance back over the past month, the stock shows a notable rise of 6.46%, and over the past year, a remarkable increase of 24.40%. These fluctuations are generating a wave of optimism...
Continue Reading
Unveiling Trump's Economic Strategy Donald Trump has officially resumed his role as President of the United States, igniting discussions within the economic landscape. As he embarks on his new term, several executive orders are expected to reshape policies in areas like immigration, climate change, and significant social programs. Trump's history suggests that his...
Continue Reading
Exploring the Growth of the Personalized Gifts Market The global personalized gifts market is experiencing significant growth, projected to increase by USD 10.76 billion from 2025 to 2029. This growth is primarily fueled by innovative product offerings and the rising trend of eco-friendly gift options. With a compound annual growth rate (CAGR) of 6.7% expected during this...
Continue Reading